Havana-. The conduct of more than 200 clinical trials to test the effectiveness of new public health products now constitutes the endorsement of the Center for Molecular Immunology of Cuba (CIM) in 29 years of fruitful work .
In the extensive list of positive results in this almost three decades, the inclusion of these investigations in a number of more than 30 thousand patients from different entities stands out, in evaluating drugs for the treatment of cancer, and other autoimmune and neurodegenerative diseases.
Added to this is the achievement of the registration of five products created in its laboratories and production plants, explained the director of clinical research at CIM, Dr. Tania Crombet, who described these achievements as milestones in the history of the institution.
The specialist emphasized that among the drugs with this condition, in Cuba and in 25 other countries, is Nimotuzumab, a therapeutic humanized monoclonal antibody used against head and neck, lung and pancreatic cancer, and it is -approved for emergency use in patients with severe. Covid-19 disease.
CIM also has the registration of Cimavax, a chemical conjugate of recombinant human epidermal growth factor for the treatment of advanced lung cancer, which has the ability to control disease progression, prolong survival and improve quality of life. , which makes it easier for the five countries to recognize its benefits.
Crombet explained that in these 29 years more than 150 thousand Cubans have been treated with CIM products and outside the country more than three million 500 thousand people have benefited from the medicines developed by researchers and technician in that biotechnological institution.
In relation to the activity abroad, the expert highlighted the participation in 50 clinical trials in Asia, Europe, Latin America, Canada and the United States, the latter country where important studies on advanced cancer are carried out with encouraging signs of 30-month survival. in patients undergoing therapies and treatments.
Of great relevance is the participation of more than five professionals in this research and clinical trials of Biocubafarma and the Ministry of Health, including hospitals and polyclinics, commented the director of clinical research of CIM,
Inaugurated on December 5, 1994 by the leader of the Cuban Revolution, Fidel Castro, CIM was born as part of his strategy to develop biotechnology based on new pharmaceutical and diagnostic-treatment products, in the difficult years of economic crisis of the decade. the 90s, known as a special period.
Currently, CIM is a high-tech company of the Biocubafarma Group, which operates with the closed-cycle principle (research-development, production and marketing), where it has three production plants and four joint ventures in China, Thailand, Singapore and the United States. Participated.